Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multimedia

John Leonard, MD
Videos
Highlights in Indolent Lymphomas From the LL&M Congress
10/23/2024
In part 1 of this expert roundtable covering updates in lymphoma from the 2024 Lymphoma, Leukemia & Myeloma Congress, John Leonard, MD, discusses research in indolent lymphomas, highlighting follicular lymphomas, with Matthew Lunning, DO,...
In part 1 of this expert roundtable covering updates in lymphoma from the 2024 Lymphoma, Leukemia & Myeloma Congress, John Leonard, MD, discusses research in indolent lymphomas, highlighting follicular lymphomas, with Matthew Lunning, DO,...
In part 1 of this expert...
10/23/2024
Lymphoma, Leukemia & Myeloma Network
Alexey Danilov, MD
Conference Coverage
Selecting Optimal Frontline Therapies for Treating Patients With CLL
10/21/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia &...
10/21/2024
Oncology
Daniel Landsberg, MD
Conference Coverage
Utilizing CAR T-Cell Therapy to Treat Patients With R/R Follicular Lymphoma
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
Evaluating the Use of MRD in Multiple Myeloma Treatment
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Joanna Rhodes, MD
Conference Coverage
Use of Targeted Agents Among Patients With R/R Follicular Lymphoma
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Lymphoma, Leukemia & Myeloma Network
Craig Sauter, MD
Conference Coverage
Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Oncology
Beth Faiman, PhD, MSN
Videos
Managing Oral Toxicities Among Patients With R/R MM Receiving Talquetamab Therapy
10/18/2024
Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.
Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.
Beth Faiman PhD, MSN, provides...
10/18/2024
APP Institute Oncology
Justin Kaner, MD
Conference Coverage
Optimizing Treatment Methods Among Patients With Newly Diagnosed AML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
Mrinal Patnaik, MD
Conference Coverage
Exploring Diagnostic Criteria and Treatment Options for Patients With CMML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Lymphoma, Leukemia & Myeloma Network
Sujith Kalmadi, MD
Sponsored
Evaluating the Evolving Multiple Myeloma Treatment Landscape
08/21/2024
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Sujith Kalmadi, MD, discusses the latest treatment and management strategies for multiple myeloma.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Sujith Kalmadi, MD, discusses the latest treatment and management strategies for multiple myeloma.
At the 2024 Great Debates &...
08/21/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

In the News

News
Venetoclax-Ibrutinib Demonstrates Long-Term Efficacy Among Patients With R/R Mantle Cell Lymphoma
09/05/2024
Combination venetoclax-ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma demonstrated durable responses and an acceptable toxicity profile, according to 7-year outcomes from the AIM clinical trial.
Combination venetoclax-ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma demonstrated durable responses and an acceptable toxicity profile, according to 7-year outcomes from the AIM clinical trial.
Combination venetoclax-ibrutinib...
09/05/2024
Lymphoma, Leukemia & Myeloma Network
News
Reduction of Specialized Follow-Ups for Patients With Asymptomatic and Low-to-Intermediate Risk CLL
09/04/2024
Study results demonstrated feasibility and safety among a subset of patients with chronic lymphocytic leukemia (CLL) who have low-to-intermediate risk CLL International Prognostic Index and CLL without need of treatment scores who ended...
Study results demonstrated feasibility and safety among a subset of patients with chronic lymphocytic leukemia (CLL) who have low-to-intermediate risk CLL International Prognostic Index and CLL without need of treatment scores who ended...
Study results demonstrated...
09/04/2024
Lymphoma, Leukemia & Myeloma Network
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Advertisement

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use